Boston Scientific Becomes Only Company With Two Drug-eluting Stent Platforms
Boston Scientific Corporation (NYSE: BSX) has announced that the PROMUS™ everolimus-eluting coronary stent system has received CE Mark approval making Boston Scientific the only company to offer two distinct approved drug-eluting stent (DES) platforms in the CE geographies. [click link for full article]
posted by Smile Community @ 3:07 AM
0 Comments:
Post a Comment
<< Home